Patents by Inventor Seema Sinha

Seema Sinha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL THYROID PEROXIDASE AUTOANTIBODY IMMUNOASSAY
    Publication number: 20240027438
    Abstract: Disclosed herein are immunoassays for detecting an anti-thyroid peroxidase antibody in a biological sample from a subject and/or diagnosing a thyroid disease in a subject. The disclosed immunoassays employ a recombinant cynomolgus monkey thyroid peroxidase (rTPO) and assess the level of anti-thyroid peroxidase antibody-induced formation or disruption of complexes comprising a solid support and the rTPO.
    Type: Application
    Filed: September 22, 2023
    Publication date: January 25, 2024
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Kayla Cortese, Saji Cherian, Paul D'Agostino, Gabriel Hammarquist, Aili Han, Kuldeep Jaggi, Maral Poladian, Niver Sahakian, Seema Sinha, Prakash Tewari, Haekyung Lee
  • Thyroid peroxidase autoantibody immunoassay
    Patent number: 11835518
    Abstract: Disclosed herein are immunoassays for detecting an anti-thyroid peroxidase antibody in a biological sample from a subject and/or diagnosing a thyroid disease in a subject. The disclosed immunoassays employ a recombinant cynomolgus monkey thyroid peroxidase (rTPO) and assess the level of anti-thyroid peroxidase antibody-induced formation or disruption of complexes comprising a solid support and the rTPO.
    Type: Grant
    Filed: April 6, 2022
    Date of Patent: December 5, 2023
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Kayla Cortese, Saji Cherian, Paul D'Agostino, Gabriel Hammarquist, Aili Han, Kuldeep Jaggi, Maral Poladian, Niver Sahakian, Seema Sinha, Prakash Tewari, Haekyung Lee
  • NOVEL THYROID PEROXIDASE AUTOANTIBODY IMMUNOASSAY
    Publication number: 20220236259
    Abstract: Disclosed herein are immunoassays for detecting an anti-thyroid peroxidase antibody in a biological sample from a subject and/or diagnosing a thyroid disease in a subject. The disclosed immunoassays employ a recombinant cynomolgus monkey thyroid peroxidase (rTPO) and assess the level of anti-thyroid peroxidase antibody-induced formation or disruption of complexes comprising a solid support and the rTPO.
    Type: Application
    Filed: April 6, 2022
    Publication date: July 28, 2022
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Kayla Cortese, Saji Cherian, Paul D'Agostino, Gabriel Hammarquist, Aili Han, Kuldeep Jaggi, Maral Poladian, Niver Sahakian, Seema Sinha, Prakash Tewari, Haekyung Lee
  • Thyroid peroxidase autoantibody immunoassay
    Patent number: 11327074
    Abstract: Disclosed herein are immunoassays for detecting an anti-thyroid peroxidase antibody in a biological sample from a subject and/or diagnosing a thyroid disease in a subject. The disclosed immunoassays employ a recombinant cynomolgus monkey thyroid peroxidase (rTPO) and assess the level of anti-thyroid peroxidase antibody-induced formation or disruption of complexes comprising a solid support and the rTPO.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: May 10, 2022
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Kayla Cortese, Saji Cherian, Paul D'Agostino, Gabriel Hammarquist, Aili Han, Kuldeep Jaggi, Maral Poladian, Niver Sahakian, Seema Sinha, Prakash Tewari, Haekyung Lee
  • NOVEL THYROID PEROXIDASE AUTOANTIBODY IMMUNOASSAY
    Publication number: 20210356459
    Abstract: Disclosed herein are immunoassays for detecting an anti-thyroid peroxidase antibody in a biological sample from a subject and/or diagnosing a thyroid disease in a subject. The disclosed immunoassays employ a recombinant cynomolgus monkey thyroid peroxidase (rTPO) and assess the level of anti-thyroid peroxidase antibody-induced formation or disruption of complexes comprising a solid support and the rTPO.
    Type: Application
    Filed: July 1, 2019
    Publication date: November 18, 2021
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Kayla Cortese, Saji Cherian, Paul D'Agostino, Gabriel Hammarquist, Aili Han, Kuldeep Jaggi, Maral Poladian, Niver Sahakian, Seema Sinha, Prakash Tewari, Haekyung Lee
  • STORAGE SOLUTION COMPOSITIONS FOR THE STABILIZATION OF PURIFIED MÜLLERIAN INHIBITING SUBSTANCE (MIS) AND METHODS OF USE AND PRODUCTION RELATED THERETO
    Publication number: 20210212311
    Abstract: Non-limiting embodiments of an improved Müllerian Inhibiting Substance storage buffer composition(s) and method(s) of stabilizing a Müllerian Inhibiting Substance in the improved storage buffer composition.
    Type: Application
    Filed: September 26, 2019
    Publication date: July 15, 2021
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Tom Chuan, Jelena Bogdanovic, Seema Sinha, Aili Han, Agata Jacewicz, Tramanh Tran
  • NON-RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN CONCENTRATE
    Publication number: 20210072266
    Abstract: A human insulin-like growth factor (IGF) binding protein stock solution and method of making the same include a non-recombinant human IGF binding protein-3 (nr-IGFBP-3) in an aqueous buffered medium. The concentration of the nr-IGFBP-3 in the stock solution ranges from about 16 micrograms per milliliter (?g/ml) to about 40 ?g/ml. A kit includes a set of calibrators for nr-IGFBP-3. The set of calibrators includes the nr-IGFBP-3 in different concentrations.
    Type: Application
    Filed: November 16, 2020
    Publication date: March 11, 2021
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Spencer Lin, Kwasi Osae-Kwapong, Omar Quraishi, Seema Sinha, Michele Smith, SunRay DiFrancesco, Ryan Spears, Dharini Rawal, Debra Hovanec-Burns, Robert Owens
  • NON-RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN CONCENTRATE
    Publication number: 20190018025
    Abstract: A human insulin-like growth factor (IGF) binding protein stock solution and method of making the same include a non-recombinant human IGF binding protein-3 (nr-IGFBP-3) in an aqueous buffered medium. The concentration of the nr-IGFBP-3 in the stock solution ranges from about 16 micrograms per milliliter (?g/ml) to about 40 ?g/ml. A kit includes a set of calibrators for nr-IGFBP-3. The set of calibrators includes the nr-IGFBP-3 in different concentrations that are within a range of from about 0.5 ?g/ml to about 16 ?g/ml, which is configured to span a suspected range of IGFBP-3 analyte levels in an immunoassay of patient samples.
    Type: Application
    Filed: December 28, 2016
    Publication date: January 17, 2019
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Spencer Lin, Kwasi Osae-Kwapong, Omar Quraishi, Seema Sinha, Michele Smith, SunRay DiFrancesco, Ryan Spears, Dharini Rawal, Debra Hovanec-Burns, Robert Owens